Superworth

Fortrea free cash flow FTRE

Cash from operations less capital spending, by quarter and over the last twelve months, from 2022.

Last 12 months, to Sep 30, 2026
$169M
Latest quarter, Q3 FY26
$52.5M
−34% on a year earlier
Fiscal year 2025
$88.3M
−63% on the year before

Fortrea's free cash flow was $169M over the twelve months to Sep 30, 2026.

In its latest quarter, Q3 FY26, it was $52.5M, down 34% on the same quarter a year before.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025$88.3M−63%
FY2024$237.3M+85%
FY2023$128.1Mn/a
FY2022n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q3 FY26$52.5M−34%$169M
Q2 FY26$19.9M+39%$196M
Q1 FY26−$25Mn/a$190.4M
Q4 FY25$121.6M+499%$88.3M
Q3 FY25$79.5Mn/a−$13M
Q2 FY25$14.3M−95%−$103.1M
Q1 FY25−$127.1Mn/a$145.1M
Q4 FY24$20.3M+126%$237.3M
Q3 FY24−$10.6Mn/a$226M
Q2 FY24$262.5M+87%$233.4M
Q1 FY24−$34.9Mn/a$111.4M
Q4 FY23$9M−9%$128.1M

Against its peers

Companies in Medical - Diagnostics & Research nearest Fortrea's size, closest first, today.

CompanyFree cash flow yield
FTREFortrea8.7%
VCYTVeracyte4.2%
CDNACareDxn/m
BLLNBillionToOne0.6%
LNTHLantheus5.9%
NRCNRC Health4.0%
CAICaris Life Sciences1.4%
BIOBio-Rad Laboratories3.6%
RVTYRevvity3.3%
MEDPMedpace3.9%
Peer median3.8%

Where Fortrea ranks

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Fortrea

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.